A new AI tool may help clinicians determine which early stage melanoma patients would likely benefit from aggressive treatment even at the onset of the disease.
A team led by investigators at Massachusetts General Hospital has determined that Omicron BA.2 is weaker than both Delta and the original Omicron variant.